Bio-Rad's clinical diagnostics segment revenues were up approximately 2 percent year over year in the quarter to $379.0 million. On a currency-neutral basis, the segment grew 3 percent due to growth in diabetes, quality controls, autoimmune, and blood typing products, as well as growth in Asia and the Americas.
DxTerity Diagnostics has appointed Brett Swansiger as chief commercialization officer. Prior to DxTerity, Swansiger held multiple positions at MDxHealth, including VP of managed care and payor strategy. Before MDxHealth, he served as VP of managed care and Asia market access for Agendia. Prior to Agendia, Swansiger help multiple positions at Prometheus Laboratories.
Asia outpaced Europe in the second half of last year on both number of deals and bulk of capital raised. In Q3, European startups raised $1.6 billion through 95 deals, compared to $1.8 billion amassed by Asian startups across 157 deals. In Q4, a similar story was at play: European startups participated in 100 rounds to raise $1.2 billion, compared to $2.14 billion* raised by Asian startups across 125 deals*.